These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17163177)

  • 1. Synergistic molecular mechanisms in hormone-sensitive breast cancer.
    Cussac AL
    Adv Exp Med Biol; 2006; 587():375-86. PubMed ID: 17163177
    [No Abstract]   [Full Text] [Related]  

  • 2. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
    Massarweh S; Schiff R
    Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.
    Sachdev D; Yee D
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):27-39. PubMed ID: 16947084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting insulin-like growth factor in breast cancer therapeutics.
    Karamouzis MV; Papavassiliou AG
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biomarkers of endocrine therapy-resistance in breast cancers].
    de Cremoux P; Debled M; Bonnefoi H; Cottu P
    Bull Cancer; 2010 Aug; 97(8):951-63. PubMed ID: 20605764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long and winding road for overcoming resistance to hormone therapy in breast cancer.
    Saji S
    Breast Cancer; 2018 Jul; 25(4):377-378. PubMed ID: 29808354
    [No Abstract]   [Full Text] [Related]  

  • 7. Ribociclib (Kisqali) for advanced or metastatic breast cancer.
    Med Lett Drugs Ther; 2017 Oct; 59(1532):e178-e179. PubMed ID: 29039822
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors.
    Toska E; Baselga J
    Clin Cancer Res; 2016 May; 22(9):2099-101. PubMed ID: 26957555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foreword. Target therapy for cancer: anti-cancer drugs targeting growth-factor signaling molecules.
    Ito F
    Biol Pharm Bull; 2011; 34(12):1773. PubMed ID: 22130228
    [No Abstract]   [Full Text] [Related]  

  • 11. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
    Santa-Maria CA; Gradishar WJ
    JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence and metastasis of breast cancer is influenced by ovarian hormone's effect on breast cancer stem cells.
    Nandy SB; Gangwani L; Nahleh Z; Subramani R; Arumugam A; de la Rosa JM; Lakshmanaswamy R
    Future Oncol; 2015; 11(6):983-95. PubMed ID: 25760978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neratinib (HKI-272) in the treatment of breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
    Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antihormonal therapy in breast cancer and mTOR inhibitors].
    Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
    Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
    [No Abstract]   [Full Text] [Related]  

  • 17. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Her2 a paradigm for targeted therapy].
    Marijon H; André F
    Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant gliomas in adults.
    Wen PY; Kesari S
    N Engl J Med; 2008 Jul; 359(5):492-507. PubMed ID: 18669428
    [No Abstract]   [Full Text] [Related]  

  • 20. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.